FI120236B - Kopolymeeri-1 parannuksia kopolymeerien seoksiin - Google Patents

Kopolymeeri-1 parannuksia kopolymeerien seoksiin Download PDF

Info

Publication number
FI120236B
FI120236B FI964600A FI964600A FI120236B FI 120236 B FI120236 B FI 120236B FI 964600 A FI964600 A FI 964600A FI 964600 A FI964600 A FI 964600A FI 120236 B FI120236 B FI 120236B
Authority
FI
Finland
Prior art keywords
copolymer
molecular weight
kda
mixture
over
Prior art date
Application number
FI964600A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964600A (fi
FI964600A0 (fi
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI120236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of FI964600A0 publication Critical patent/FI964600A0/fi
Publication of FI964600A publication Critical patent/FI964600A/fi
Application granted granted Critical
Publication of FI120236B publication Critical patent/FI120236B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
FI964600A 1994-05-24 1996-11-15 Kopolymeeri-1 parannuksia kopolymeerien seoksiin FI120236B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US24803794 1994-05-24
US34424894A 1994-11-23 1994-11-23
US34424894 1994-11-23
US9506551 1995-05-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (3)

Publication Number Publication Date
FI964600A0 FI964600A0 (fi) 1996-11-15
FI964600A FI964600A (fi) 1996-12-05
FI120236B true FI120236B (fi) 2009-08-14

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964600A FI120236B (fi) 1994-05-24 1996-11-15 Kopolymeeri-1 parannuksia kopolymeerien seoksiin

Country Status (31)

Country Link
US (11) US5800808A (ru)
EP (1) EP0762888B1 (ru)
JP (2) JPH10500955A (ru)
KR (1) KR100403750B1 (ru)
CN (2) CN1174753C (ru)
AT (1) ATE212857T1 (ru)
AU (1) AU2602195A (ru)
BR (2) BR9507758A (ru)
CA (1) CA2191088C (ru)
CZ (1) CZ292247B6 (ru)
DE (2) DE69525340T2 (ru)
DK (1) DK0762888T3 (ru)
EE (1) EE03423B1 (ru)
ES (1) ES2172586T3 (ru)
FI (1) FI120236B (ru)
GE (1) GEP20002205B (ru)
HK (1) HK1008657A1 (ru)
HU (1) HU223473B1 (ru)
IL (2) IL113812A (ru)
LU (1) LU90987I2 (ru)
MD (1) MD1443G2 (ru)
NL (1) NL300096I2 (ru)
NO (1) NO324528B1 (ru)
NZ (1) NZ287335A (ru)
PL (1) PL181026B1 (ru)
PT (1) PT762888E (ru)
SI (1) SI0762888T1 (ru)
SK (1) SK283699B6 (ru)
TJ (1) TJ392B (ru)
UA (1) UA62908C2 (ru)
WO (1) WO1995031990A1 (ru)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HU229289B1 (en) 1998-09-25 2013-10-28 Yeda Res & Dev Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) * 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
MXPA02007106A (es) * 2000-01-20 2002-12-13 Mcinnis Patricia A El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para terapia neuroprotectora.
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CA2400374A1 (en) * 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
HUP0302333A3 (en) * 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
NZ520282A (en) * 2000-06-07 2004-09-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
SI1429800T1 (sl) * 2001-12-06 2009-08-31 Yeda Res & Dev Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
MXPA05007329A (es) 2003-01-07 2005-09-30 Yeda Res & Dev Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
EP1592384B1 (en) * 2003-01-21 2012-10-31 Yeda Research And Development Co., Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
KR20060097020A (ko) * 2003-10-31 2006-09-13 테바 파마슈티컬 인더스트리즈 리미티드 약물 전달용 나노입자
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
JP4808631B2 (ja) 2003-12-09 2011-11-02 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン
US20090214580A1 (en) * 2004-02-02 2009-08-27 Houghten Richard A Peptide mixtures with immunomodulatory activity
WO2005085323A2 (en) * 2004-03-01 2005-09-15 Peptimmune, Inc. Methods and compositions for treatment of autoimmune diseases
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
EP1750742A2 (en) 2004-05-07 2007-02-14 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
NZ552075A (en) 2004-06-25 2009-08-28 Id Biomedical Corp Compositions and methods for treating neurological disorders
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
PT2361924E (pt) 2004-09-09 2014-03-13 Teva Pharma Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
JP5294635B2 (ja) * 2004-11-29 2013-09-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2016095A2 (en) 2006-04-13 2009-01-21 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
AU2007244643B2 (en) * 2006-04-28 2013-05-02 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
EP2046366B1 (en) 2006-06-28 2016-08-31 Yeda Research And Development Company Limited Copolymer-1 for treatment of age-related macular degeneration
CN101511862A (zh) * 2006-07-05 2009-08-19 莫门塔制药股份有限公司 制备共聚物-1的改进方法
AU2008265692A1 (en) 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
US8993722B2 (en) * 2007-07-31 2015-03-31 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
AU2008311897B2 (en) 2007-10-16 2015-03-26 Declion Holdings Llc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
HUE025042T2 (en) * 2008-08-07 2016-07-28 Sigma Aldrich Co Llc High-yield production of low molecular weight polylysine and poliornitine
CN102112485B (zh) * 2008-08-07 2013-11-27 台湾神隆股份有限公司 乙酸格拉默(glatiramer acetate)的合成
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
ES2523732T5 (es) 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
AU2009347384B2 (en) * 2009-06-04 2014-10-23 Council Of Scientific & Industrial Research A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
EP2275086B1 (en) 2009-07-15 2012-03-14 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
DK3199172T3 (en) 2009-08-20 2018-10-08 Yeda Res & Dev DOSAGE regimen for multiple sclerosis
CN107661490B (zh) 2010-01-04 2021-12-31 Mapi医药公司 包含格拉默或其药用盐的储药系统
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2523668A1 (en) 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
KR20130062936A (ko) * 2010-04-27 2013-06-13 닥터 레디스 레보러터리즈 리미티드 폴리펩티드 및 그의 염의 제조
US20110287048A1 (en) 2010-05-20 2011-11-24 Round June L Antigen Specific Tregs and related compositions, methods and systems
CN103080747B (zh) 2010-07-29 2016-04-27 雷迪博士实验室有限公司 醋酸格拉默分子量标记
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
EP2675824B1 (en) 2011-02-14 2017-09-27 USV Private Limited Copolymer-1, process for preparation and analytical methods thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
DK2774639T3 (en) 2013-03-08 2015-01-12 Teva Pharma Reusable injection device for a syringe
SI2774640T1 (sl) 2013-03-08 2015-04-30 Teva Pharmaceutical Industries, Ltd. Injektorska naprava za brizgo, primerna za ponovno uporabo
US10344330B2 (en) 2013-03-14 2019-07-09 Mylan Inc. Glatiramer acetate response biomarker mRNA potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP2016533728A (ja) * 2013-10-24 2016-11-04 マイラン・インコーポレイテッドＭｙｌａｎ Ｉｎｃ． 酢酸グラチラマー製品の免疫学的同一性を評価するためのヒトｔ細胞株アッセイ
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
ES2744179T3 (es) 2015-09-24 2020-02-24 Chemi Spa Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
ES2707500T3 (es) 2015-11-23 2019-04-03 Chemi Spa Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
BR112019003131A2 (pt) 2016-08-28 2019-05-21 Mapi Pharma Ltd. processo para preparar micropartículas contendo acetato de glatirâmero
CA3035147A1 (en) 2016-08-31 2018-03-08 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
IE59233B1 (en) 1985-06-18 1994-01-26 Univ Emory Use of biologically active copolymers for the manufacture of a medicament for stimulating the growth of an animal
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) * 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
JP3345816B2 (ja) * 1991-11-12 2002-11-18 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー コラーゲン様ポリペプチド類
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AU7368798A (en) 1997-05-06 1998-11-27 Quanta Vision Tissue analysis apparatus
MXPA02007106A (es) * 2000-01-20 2002-12-13 Mcinnis Patricia A El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para terapia neuroprotectora.
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
SI0762888T1 (en) 2002-08-31
JP2003105000A (ja) 2003-04-09
US6054430A (en) 2000-04-25
NO964976L (no) 1997-01-23
SK283699B6 (sk) 2003-12-02
US5981589A (en) 1999-11-09
NO324528B1 (no) 2007-11-12
US8367605B2 (en) 2013-02-05
EE9600170A (et) 1997-06-16
NL300096I1 (nl) 2002-10-01
US6342476B1 (en) 2002-01-29
PT762888E (pt) 2002-07-31
CZ292247B6 (cs) 2003-08-13
CN1152874A (zh) 1997-06-25
JPH10500955A (ja) 1998-01-27
EP0762888A4 (ru) 1997-04-16
DE69525340T2 (de) 2002-09-19
UA62908C2 (ru) 2004-01-15
ES2172586T3 (es) 2002-10-01
CA2191088A1 (en) 1995-11-30
KR970703154A (ko) 1997-07-03
CN1174753C (zh) 2004-11-10
EE03423B1 (et) 2001-06-15
FI964600A (fi) 1996-12-05
IL113812A (en) 2000-06-29
IL133890A0 (en) 2001-04-30
US20050171286A1 (en) 2005-08-04
US6620847B2 (en) 2003-09-16
KR100403750B1 (ko) 2006-02-13
US20040106554A1 (en) 2004-06-03
US20120077754A1 (en) 2012-03-29
MD1443F1 (en) 2000-04-30
PL181026B1 (pl) 2001-05-31
EP0762888B1 (en) 2002-02-06
BRPI9507758B1 (pt) 2021-03-16
EP0762888A1 (en) 1997-03-19
US5800808A (en) 1998-09-01
HK1008657A1 (en) 1999-05-14
DK0762888T3 (da) 2002-05-27
SK149396A3 (en) 1997-08-06
MD1443G2 (ru) 2000-11-30
HUT75672A (en) 1997-05-28
PL317331A1 (en) 1997-04-01
JP3715600B2 (ja) 2005-11-09
CA2191088C (en) 2004-09-28
NL300096I2 (nl) 2003-02-03
AU2602195A (en) 1995-12-18
FI964600A0 (fi) 1996-11-15
US20030064914A1 (en) 2003-04-03
US6939539B2 (en) 2005-09-06
CN1310673C (zh) 2007-04-18
DE10299030I1 (de) 2003-01-23
LU90987I2 (fr) 2003-02-25
CZ341096A3 (en) 1997-06-11
US6048898A (en) 2000-04-11
US7199098B2 (en) 2007-04-03
TJ392B (en) 2004-10-13
WO1995031990A1 (en) 1995-11-30
NZ287335A (en) 1999-02-25
BR9507758A (pt) 1997-09-23
HU9603243D0 (en) 1997-01-28
IL113812A0 (en) 1995-08-31
GEP20002205B (en) 2000-08-25
DE69525340D1 (de) 2002-03-21
CN1626238A (zh) 2005-06-15
HU223473B1 (hu) 2004-07-28
US6362161B1 (en) 2002-03-26
US7625861B2 (en) 2009-12-01
US20070117757A1 (en) 2007-05-24
ATE212857T1 (de) 2002-02-15
NO964976D0 (no) 1996-11-22

Similar Documents

Publication Publication Date Title
FI120236B (fi) Kopolymeeri-1 parannuksia kopolymeerien seoksiin
RU2198900C2 (ru) Усовершенствованный сополимер-1 и способ его получения
AU741590B2 (en) Copolymer-1 improvements in compositions of copolymers
AU2004202245B2 (en) Copolymer-1 Improvements in Compositions of Copolymers
AU775214B2 (en) Copolymer-1 improvements in compositions of copolymers
RU2402576C1 (ru) Пептидный сополимер, способ его получения и фармацевтическая композиция на его основе
Matsoukas et al. Designing peptide mimetics for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120236

Country of ref document: FI

MA Patent expired